STARTRK-2 is an open-label, global, Phase 2 basket study* of entrectinib (RXDX-101) for the treatment of patients with locally advanced or metastatic solid tumours. Cholangiocarcinoma patients would be screened for an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene rearrangement.
This trial is currently recruiting in the UK at:
- The Sarah Cannon Research Institute, London
- Addenbrookes Hospital, Cambridge
- The Christie Hospital, Manchester
ClinicalTrials.gov identifier: NCT02568267
For more information go to: https://clinicaltrials.gov/ct2/show/NCT02568267
*The “basket” design means that patient outcomes will be analysed separately, by “basket”, according to tumour type and gene rearrangement.Back to previous page